OTCMKTS:CASBF CanSino Biologics (CASBF) Stock Price, News & Analysis C$3.86 0.00 (0.00%) As of 05/4/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesBuy This Stock About CanSino Biologics Stock (OTCMKTS:CASBF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CanSino Biologics alerts:Sign Up Key Stats Today's RangeC$3.86▼C$3.8650-Day RangeC$3.75▼C$4.2652-Week RangeC$3.75▼C$6.99VolumeN/AAverage Volume425 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview CanSino Biologics Inc. is a China-based biopharmaceutical company focused on the research, development and commercialization of vaccine products. Headquartered in Tianjin, the company leverages an adenovirus vector platform to develop single-dose and recombinant vaccines targeting a range of infectious diseases. CanSino’s pipeline includes its authorized COVID-19 vaccine, Convidecia (Ad5-nCoV), as well as candidates for Ebola, influenza and other pathogens. Since its founding in 2009, CanSino has built end-to-end capabilities spanning antigen discovery, process development and large-scale manufacturing. The company’s vaccine technologies are underpinned by a proprietary adenovirus type 5 vector system that supports streamlined production and robust immune responses. CanSino’s facilities are designed to meet international quality standards, enabling it to supply both domestic and overseas markets. CanSino Biologics serves a broad geography, having secured emergency use authorizations or conditional approvals in China, Mexico, Pakistan, Hungary and several other countries for its COVID-19 vaccine. The company maintains partnerships with regional manufacturers and health authorities to facilitate distribution in Asia, Latin America and Europe. CanSino is led by a management team with extensive experience in vaccine science, regulatory affairs and commercial operations, positioning it as a key player in the global immunization landscape.AI Generated. May Contain Errors. Read More Receive CASBF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CanSino Biologics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CASBF Stock News HeadlinesCanSino Biologics Sets April 28 Board Meeting to Approve Q1 2026 ResultsApril 16, 2026 | tipranks.comCanSino Biologics Publishes Audited 2025 Annual Results and Readies Full ReportMarch 30, 2026 | tipranks.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.May 5 at 1:00 AM | Profits Run (Ad)CanSino Biologics Sets March 30 Board Meeting to Approve 2025 ResultsMarch 17, 2026 | tipranks.comCanSino Biologics Wins PIC/S GMP Nod for Key Conjugate VaccinesMarch 5, 2026 | tipranks.comCanSino Wins China Nod to Extend Use of Menhycia Pediatric VaccineFebruary 24, 2026 | tipranks.comCanSinoBIO at WGS 2026: Accelerating Global Access to Innovative VaccinesFebruary 9, 2026 | prnewswire.comCanSino Wins China Trial Nod for First-in-Class 24-Valent Pneumococcal VaccineJanuary 5, 2026 | tipranks.comSee More Headlines CASBF Stock Analysis - Frequently Asked Questions How have CASBF shares performed this year? CanSino Biologics' stock was trading at C$4.75 at the beginning of 2026. Since then, CASBF stock has decreased by 18.7% and is now trading at C$3.86. How do I buy shares of CanSino Biologics? Shares of CASBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:CASBF CIKN/A Webwww.cansinotech.com Phone400-922-2099FaxN/AEmployees1,494Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (OTCMKTS:CASBF) was last updated on 5/5/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSell 99% of Your Stocks, Do THIS Instead…Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...The Oxford Club | SponsoredTrade this between 9:30 and 10:45 am ESTThe first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredElon Unveils AI Passive Income Stream for Millions of AmericansDuring Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...InvestorPlace | SponsoredInvest in SpaceX Before IPOSpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...NXT Wave Research | SponsoredURGENT: $2 Gold Stock With Major DiscoveryA $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CanSino Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CanSino Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.